| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study is developing a new diagnostic method to evaluate the effectiveness of the antibody treatment in digestive cancer with heterogeneity. We evaluated Her2 expression in primary tumor or the metastasis lymph node and we confirmed the heterogeneity in gastric cancer. We recognized a difference Her2 expression pattern between the primary lesion and the lymph node in six of ten cases. LP-ICG-C18 was made the liposome that can be observed with fluorescence imaging system. The identification of tumor including LP-ICG-C18 was easy by using near-infrared fluorescence imaging system. Furthermore, we confirmed the antigen-antibody reaction with Her2-LP-ICG-C18. We established Quantum Dots Conjugated with Monoclonal Anti-HER2 Antibody (ICG-QD), and the signal which was more powerful. It was thought that it became the base to a diagnosis in the preoperation of Her2-positive tumor using this probe.
|
